Gossamer Bio (NASDAQ:GOSS) Lowered to “Neutral” Rating by Wedbush

Gossamer Bio (NASDAQ:GOSS) was downgraded by equities research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $1.00 price objective on the stock, down from their previous price objective of $6.00. Wedbush’s target price suggests a potential upside of 138.10% from the company’s current price.

A number of other equities analysts also recently commented on GOSS. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Barclays downgraded shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday. Leerink Partners downgraded shares of Gossamer Bio to a “market perform” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $6.67.

Gossamer Bio Price Performance

Shares of GOSS stock opened at $0.42 on Tuesday. Gossamer Bio has a fifty-two week low of $0.33 and a fifty-two week high of $3.87. The stock’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.68. The firm has a market cap of $97.21 million, a P/E ratio of -0.61 and a beta of 1.93.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Gossamer Bio by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after acquiring an additional 598,981 shares during the last quarter. State Street Corp boosted its stake in Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares during the period. Acadian Asset Management LLC grew its holdings in Gossamer Bio by 12.4% in the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after buying an additional 787,909 shares during the last quarter. Geode Capital Management LLC grew its holdings in Gossamer Bio by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock valued at $15,109,000 after buying an additional 183,183 shares during the last quarter. Finally, Corient Private Wealth LLC increased its position in Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares during the period. Institutional investors own 81.23% of the company’s stock.

Key Headlines Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: Gossamer said it will still seek FDA approval for seralutinib despite the late‑stage trial miss — this leaves a regulatory/appeal pathway that could preserve some future value. Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
• Positive Sentiment: Seralutinib is being developed jointly with the Chiesi Group under an existing collaboration, which may share development costs and options for next steps. Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study
• Neutral Sentiment: Company released topline PROSERA results and held a call to discuss the data; the press release and transcript provide detail but didn’t change the headline outcome (primary endpoint not met). PROSERA Phase 3 topline results transcript
• Negative Sentiment: Topline data showed seralutinib failed to meet the trial’s primary endpoint in PAH — the core reason investors are selling and the primary driver of the stock’s decline. Gossamer Bio’s experimental lung condition drug fails in late-stage trial (Reuters)
• Negative Sentiment: Market reaction: major outlets report a steep sell‑off and trading was temporarily halted as the news was released, amplifying volatility and liquidity concerns. Gossamer Bio stock tumbles 80% on trial miss
• Negative Sentiment: Potential litigation risk: multiple law firms (Block & Leviton, Johnson Fistel) are soliciting GOSS investors and investigating potential securities claims, which could lead to lawsuits or settlements. Block & Leviton solicitation (GlobeNewswire) Johnson Fistel solicitation (GlobeNewswire)

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.